title: Can response duration after the first rituximab treatment be used in timing of rituximab retreatment?
authors.forename: N
authors.initials: N
authors.lastname: van Herwaarden
authors.forename: A
authors.initials: A
authors.lastname: van der Maas
authors.forename: T L
authors.initials: TL
authors.lastname: Jansen
authors.forename: E A J
authors.initials: EA
authors.lastname: Dutmer
authors.forename: A
authors.initials: A
authors.lastname: Hartkamp
authors.forename: P L C M
authors.initials: PL
authors.lastname: van Riel
authors.forename: W
authors.initials: W
authors.lastname: Kievit
authors.forename: B J F
authors.initials: BJ
authors.lastname: van den Bemt
authors.forename: A A
authors.initials: AA
authors.lastname: den Broeder
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab